Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product ...(t stage company) Condensed...),Health

Condensed Consolidated Statements of Operations

(unaudited, in thousands except per share data)

Period from

December 19,

2000

Three Months Ended Six Months Ended (inception) to

June 30, June 30, June 30,

2008 2007 2008 2007 2008

Revenue $- $- $- $- $6,945

Operating expenses:

Research and

development 15,698 10,142 30,391 20,377 173,509

General and

administrative 4,802 4,017 9,264 7,602 54,327

Acquired in-process

research and

development - - - - 3,916

Total operating

expenses 20,500 14,159 39,655 27,979 231,752

Loss from operations (20,500) (14,159) (39,655) (27,979) (224,807)

Interest and other

income, net 729 1,481 1,809 2,538 13,001

Interest expense (242) (244) (533) (479) (3,179)

Loss before

noncontrolling interest

in Symphony Allegro,

Inc. (20,013) (12,922) (38,379) (25,920) (214,985)

Loss attributed to

noncontrolling interest

in Symphony Allegro,

Inc. 5,891 2,644 9,648 4,726 22,159

Net loss $(14,122) $(10,278) $(28,731) $(21,194) $(192,826)

Basic and diluted net

loss per share $(0.43) $(0.36) $(0.90) $(0.81)

Shares used to compute

basic and diluted net

loss per share
'/>"/>